

Index

<p>activins, 8, 200</p> <p>acute respiratory distress syndrome (ARDS), 162</p> <p>adenomyosis</p> <ul style="list-style-type: none">myometrial cyst, 267ultrasound monitoring for ovulation induction, 267–268 <p>adjuncts for ovarian stimulation, 189</p> <ul style="list-style-type: none">androgens, 194–195dexamethasone, 190dopamine agonists, 194estrogen pretreatment, 190GnRH agonists, 189GnRH antagonists, 189–190growth hormone, 193human chorionic gonadotropin, mini-dose, 192low-dose aspirin, 192–193metformin, 190–192ongoing research, 195oral contraceptive pretreatment, 190risk/benefit ratio, 196 <p>adjuvant therapy</p> <ul style="list-style-type: none">definition, 105poor responders, 105, 112–113 <p>age</p> <ul style="list-style-type: none">antral follicle count correlation, 101chronological and ovarian reserve, 312euploid embryos associated with, 101poor responders, 203 <p>albumin, intravenous, OHSS prevention, 149–150</p> <p>treatment, 158, 160</p> <p>amenorrhea</p> <ul style="list-style-type: none">anovulatory patients, 15FSH and LH combination treatment, 170, 208hyperprolactinemia, 231, 232, 237hypogonadotropic, 208, 210low ovarian reserve marker, 105 <p>anastrozole, 6, 10, 18</p> <p>androgens</p> <ul style="list-style-type: none">adjunct, 194–195adjuvant for poor responders, 112	<p>letrozole, ovarian androgens increased by, 195</p> <p>production role of LH, 199</p> <p>anovulation, hypogonadotropic, 18, 79</p> <p>anovulatory patients, 15–24</p> <ul style="list-style-type: none">antiestrogens, 19aromatase inhibitors, 8, 18–19effectiveness, 124clomiphene citrate, 2–3, 5, 19complications of ovarian stimulation, 19, 23–24diet restriction, 17exercise, 18follicle development, 24gonadotropin therapy, 20hCG, 18, 20hypogonadotropic, 18inositol, 20, 21insulin resistance, 20insulin sensitizers, 20–21, 133–134interventions, 15–24laparoscopic electrocoagulation of the ovaries, 21–22lifestyle interventions, 16–18metformin, 20–21normogonadotropic, 18–19outcome of treatment, 22–23ovarian hyperstimulation syndrome, 23–24overweight/obesity, 16–17pharmacological interventions, 18–21smoking cessation, 17tamoxifen, 19weight reduction, 16–17WHO criteria, 15 <p>anterior pituitary</p> <ul style="list-style-type: none">Pit-1 gene, 223prolactin secretion, 225 <p>antibiotics, preoperative prophylaxis, OHSS, 161</p> <p>antidepressants, hyperprolactinemia induction, 232</p> <p>antiestrogens</p> <ul style="list-style-type: none">anovulatory patients, 19intrauterine insemination with mild ovarian hyperstimulation, 31	<p>antihypertensive agents, hyperprolactinemia induction, 230</p> <p>anti-Müllerian hormone (AMH)</p> <ul style="list-style-type: none">follicular recruitment, GnRH agonist use, treatment response, 60folliculogenesis regulation, 200laparoscopic ovarian diathermy, 132OHSS risk marker, 134ovarian reserve, antral follicle count combination, 101ovarian response prediction, 110, 166, 273, 312polycystic ovarian syndrome, 134poor responders, 101, 110 <p>antipsychotic medication</p> <ul style="list-style-type: none">hyperprolactinemia induction, 229hypogonadism, 237 <p>antral follicle count (AFC)</p> <ul style="list-style-type: none">age correlation, 101measurement technique, 272–273ovarian reserve marker, 312ovarian response prediction, 167, 273poor responders, 101, 110 <p>antral follicles, estimated recruitment each menstrual cycle, 166</p> <p>aromatase inhibitors, 1, 6–10</p> <ul style="list-style-type: none">adverse effects, 9, 19anovulatory patients, 8, 18–19effectiveness, 124coagulation disorders, 9early generation, problems with endometriosis, 9fertility preservation in estrogen-dependent malignancy, 9first generation, 6injectable gonadotropins, concomitant use, 8intrauterine insemination with mild ovarian hyperstimulation, 30laparoscopic ovarian surgery comparison, 251outcome of treatment, 10ovarian stimulation mechanism, 6–8, 22
---	--	--

Index

- aromatase inhibitors (cont.)
 - role, 8
 - polycystic ovarian syndrome, 1, 8–9, 124–125
 - pregnancy outcome, 10
 - safety, 9
 - third-generation, 6
 - advantages
 - women benefiting, 8
- ascites
 - IVF, 195
 - OHSS, 142, 145, 163
 - management, 158, 161–162
 - OHSS, management
 - pigtail catheter placement, 162
- ascorbic acid, progesterone
 - combination for luteal phase support, 294
- aspirin
 - low-dose adjunct, 192–193
 - in OHSS reduction, 193
 - progesterone combination for luteal phase support, 295
- bariatric surgery
 - anovulatory patients, 17
 - polycystic ovarian syndrome, 121
- bilateral enlarged cystic ovaries, OHSS, 141
- bone morphogenetic protein-15, 200
- Bologna criteria, poor responders, 101, 109
- bone morphogenetic protein-15, OHSS prediction, 200
- bromocriptine, 149, 228, 233
- cabergoline
 - high responders, 194
 - hyperprolactinemia treatment, 233–234
 - OHSS prevention, 146, 149, 194
- calcium gluconate infusion, OHSS prevention, 150
- cancer patients, fertility
 - preservation, luteal phase stimulation, 93
- catheter, pigtail, placement for ascites management in OHSS, 162
- cellular adhesion molecules (CAMs), 175
- cetrorelix, 66–67
 - natural cycle IVF with GnRH antagonists, 70–71
 - OHSS prevention, 135
 - older patients, 74
 - outcome, 74
- chest wall injury, hyperprolactinemia, 232
- clomiphene (clomifene) citrate, 1–6
 - administration regimens, 2–3, 19
 - adverse effects, 1, 3–6, 19
 - anovulatory patients, 2–3, 5, 19
 - antiestrogenic effects, 5–6, 123
 - chemical structure, 2
 - congenital anomalies, 4
 - dexamethasone combination, 190
 - dosage rates, 2, 19, 123
 - efficacy, 123
 - endometrium effects, 5
 - GnRH antagonist combination, 69
 - intrauterine insemination with
 - mild ovarian hyperstimulation, 30
 - laparoscopic ovarian surgery
 - comparison, 251
 - letrozole comparison, 22, 124–125
 - LH levels increased by, 200
 - luteal phase stimulation, 95
 - mechanism of action, 2, 19
 - metformin, combined treatment, 125–126
 - multigestation risk, 3, 123
 - outcome, 3
 - ovarian cancer risk, 4, 19, 124
 - ovarian diathermy comparison, 132
 - ovarian hyperstimulation syndrome, 3
 - ovulation and live birth
 - prediction, 24
 - pharmacokinetics, 2
 - polycystic ovarian syndrome, 122–124
 - poor responders, 111
 - pregnancy
 - loss, 4
 - rate, 1, 19, 22
 - risk, 1
 - resistance, 5
 - causes, 5–6
 - managing, 5, 133, 148
 - predictors, 123
 - serum FSH, LH, and estradiol, 200
- clomiphene citrate challenge test (CCCT), 313
- coagulation disorders, aromatase inhibitors, 9
- coasting
 - definition, 146
 - luteal, 294
 - OHSS
 - GnRH antagonists, 73–74
 - prevention, 146, 147
 - congenital anomalies, clomiphene citrate, 4
- CONSORT algorithm, 168, 313, 315
- controlled ovarian hyperstimulation (COH)
 - adjuvants, 112–113
 - elective freeze-all embryos policy, benefits, 255
 - see also* freeze-all approach
 - LH surge, GnRH antagonist for prevention, 145–146
 - medication protocols, long-term effects, 255
 - multiple follicle development, 48
 - poor responders, 110
 - recombinant LH use, 70, 72
- controlled ovarian stimulation (COS)
 - asynchronous follicle development, 103
 - defining response, 311
 - effect of endometrial receptivity and gene expression, 255–256
 - effects on embryo, 256
 - incidence of poor ovarian response, 101
 - luteal phase defect, etiology, 302
 - polycystic ovarian syndrome, 132–137
- corifollitropin alfa, poor responders, 111
- Creutzfeldt–Jakob disease (CJD), iatrogenic with gonadotropin use, 79
- cryopreservation, embryo(s), survival and fertilization rates, 256
- cysts, *see* ovarian cysts
- cytokines, 175–176
- dehydroepiandrosterone (DHEA), poor responders, 105, 112, 195
- dermoid cysts, 275–276
- dexamethasone
 - adjunct, 190
 - clomiphene citrate combination, 190
 - polycystic ovarian syndrome, 126–127
- diet restriction, anovulatory patients, 17
- diuretics, OHSS treatment, 160, 161
- dopamine
 - OHSS treatment, 194
 - prolactin secretion regulation, 226, 227
- dopamine agonists
 - adjunct, 194
 - categories, 233
 - efficacy, 236
 - galactorrhea treatment, 233
 - GnRH antagonist combination, 148
 - hyperprolactinemia, 233–236
 - long-term effects, 194
 - mechanism of action, 150

- OHSS prevention, 148–149, 194
 - withdrawal, 236
 - double stimulation (Shanghai protocol)
 - efficacy, 98
 - follicular and luteal phases, 98
 - hCG use, 98
 - ploidy, 98
 - safety, 98
 - dydrogesterone, 97, 291, 296
 - ectopic pregnancy
 - aromatase inhibitors, 124
 - OHSS, 160, 161, 163
 - elective freeze-all strategy, *see* freeze-all approach
 - elective single embryo transfer (eSET), 88, 167
 - electrocautery, *see* ovarian cautery
 - electrolyte replacement, OHSS treatment, 161
 - embryo banking strategy, poor responders, 113
 - embryo transfer
 - deferred, 255
 - donor counseling, 88–89
 - elective freeze-all policy, 258
 - endometrial receptivity, 278, 290
 - in vitro maturation, 87
 - see also* frozen embryo transfer (FET)
 - embryo(s)
 - controlled ovarian stimulation, effects, 256
 - cryopreservation, 49
 - introduction of, 256
 - survival and fertilization rates, 256
 - elective freeze-all policy, 37, 50–51, 255–261
 - see also* freeze-all approach
 - personalized embryo transfer, feasibility, 178
 - vitricification, 256
 - empty follicle syndrome (EFS)
 - GnRH agonist-triggered cycles, 283, 284
 - mutant LHCGR, 103
 - enclomiphene, 2
 - Endometrial Function Test, 177
 - endometrial receptivity, 173–180
 - affecting factors
 - endometrial thickness, 179
 - endometriosis, 179
 - ethnicity, 179
 - microbiome, 179
 - obesity, 178
 - assessment tools, 176–178
 - Endometrial Function Test, 177
 - E-tegrity test, 177
 - LH surge, 177
 - menstrual cycle, 177
 - natural killer cells, 176, 177
 - Noyes dating criteria, 176
 - omics sciences, 177–178, 185
 - pinopodes, 176
 - ultrasonography, 177
 - concept introduction, 182
 - effects of supraphysiological circulating hormone levels, 185–186
- Endometrial Receptivity Analysis (ERA) test, 178
- ethnicity, 179
- freeze-all policy, 255–256
- genetic considerations, 180
- implantation window, 173–174
 - delayed, 174
- importance of assessing, 180
- markers, 174–176, 185
 - cellular adhesion molecules, 175
 - cytokines, 175–176
 - growth factors, 176
 - microRNAs, 176
 - natural killer cells, 176
 - prostaglandins, 176
- optimal period, detection, 182
- personalized embryo transfer, feasibility, 178
- relationship with ovarian response, 167
- required stimuli, 173
- steroid hormones during implantation, 182–183
 - mechanism of action, 183–185
- endometrioma, 275
- endometriosis
 - aromatase inhibitors, 9
 - association with natural killer cells, 177
 - related to infertility, 179
- endometrium
 - clomiphene citrate effects, 5
 - gene expression disturbances, 255–256
 - polyps, 269
 - preparation for embryo transfer, 259
 - responsibility for high percentage of infertility problems, 173
 - thickness
 - effect on receptivity, 179
 - increased by hCG, 284
- ERK1 and ERK2, 217–218
- estradiol (E2)
 - adjuvant treatment for poor responders, 112
 - influence of progesterone, 97
 - luteal phase support, 305–306
 - progesterone combination, 293
- estrogen
 - adjunct for poor responders, 190
 - endometrial preparation, 259
 - hyperprolactinemia treatment, 236–237
 - implantation role, 182–183
 - IVF treatment, implantation failure, 185
 - mechanism of action during implantation, 183–185
 - modulators, 1
 - pretreatment in
 - hypogonadotropic hypogonadism, 216
 - prolactin secretion regulation, 226
 - reduction by aromatase inhibitors, 8, 9
- exercise, anovulatory patients, 18
- factor V, 161
- fertility preservation
 - cancer patients, 93
 - estrogen-dependent malignancies, 9
- fibroids
 - posterior intramural, 266
 - submucous, 266
 - uterine, 265–267
- follicle(s)
 - development, monitoring, 24
 - flushing, poor responders, 104
 - multiple, 15, 55
 - recruitment, wave theory, 114
- follicle-stimulating hormone (FSH)
 - adverse effects, 82
 - dose increase with GnRH antagonists, 69
 - exogenous LH supplementation, 201–203, 205
 - FSH window, 166
 - individualized dosing, 169, 316
 - isoforms, 80–81
 - LH pretreatment in
 - hypogonadotropic hypogonadism, 212
 - LH supplementation in
 - hypogonadotropic hypogonadism, 203
 - LH surge, 79
 - main action, 199
 - molecule, 80–81
 - OHSS risk, 82
 - ovarian reserve marker, 312
 - recombinant
 - development, 170
 - effectiveness, 82
 - hMG comparison, 202
 - OHSS risk, 82
 - production, 80
 - virus risk, 80
 - role in folliculogenesis, 199

Index

- follicle-stimulating hormone (cont.)
 - stimulation protocols, ovarian reserve marker-based algorithms, 313–314
 - two-cell two-gonadotropin hypothesis, 199, 208
 - follicular phase
 - double stimulation (Shanghai protocol), 98
 - stimulation, luteal phase comparison, 94–95
 - follicular recruitment
 - anti-Müllerian hormone levels, 60
 - dynamics, 59–60
 - GnRH agonist use, 60
 - folliculogenesis
 - implantation failure, 182–186
 - local regulators, 200
 - physiology of, 199–200
 - role of FSH and LH, 199
 - follitropin alfa, 80, 169
 - follitropin beta, 80
 - follitropin delta, 169
 - individualized protocol, outcome, 316
 - follitropin epsilon, 80
 - freeze-all approach
 - agonist triggering, 256–257
 - COS effects on embryo, 256
 - endometrial preparation, 259
 - endometrial receptivity, 255–256
 - GnRH agonist-triggered cycles, 286
 - high progesterone, 185
 - natural cycle frozen embryo transfer (FET), 258–259
 - outcomes
 - perinatal, 260–261
 - pregnancy, 259–260
 - poor responders, 102, 104, 113
 - preimplantation genetic screening, 258
 - premature progesterone elevation, 257–258
 - process, 258–259
 - reasons for, 255–256
- freeze-all approach, OHSS
 - prevention, 37, 50–51, 150, 255–261
- frozen embryo transfer (FET)
 - natural cycle, 258–259
 - outcomes in polycystic ovarian syndrome, 259
- functional cysts, 58, 276
- galactorrhea
 - hyperprolactinemia, 231
 - spontaneously occurring, 233
- genetic screening, 86, 258
- glucocorticoids, effects, 190, 294
- gonadotropin surge-attenuating factor (GnSAF), 200
- gonadotropin therapy, 79–83
 - adverse effects, 82
 - anovulatory patients, 20
 - chromosomal abnormality risk, 48–49
 - complications, 20
 - effectiveness, 81–82
 - historical aspects, 79–80
 - hypogonadotropic hypogonadism, 210–211
 - complications, 213–214
 - outcome, 212–213
 - iatrogenic CJD, 79
 - individualized dosing, 168–170, 315–316
 - injectable, 8
 - intrauterine insemination with mild ovarian hyperstimulation, 30
 - laparoscopic ovarian surgery comparison, 251
 - low-dose vs. high-dose, 42
 - mechanism of action, 20
 - OHSS
 - prevention, 82
 - risk, 82
 - oocyte donation, 86
 - optimal standard dose, 168
 - oral administration, development, 80
 - outcome of treatment, 20
 - ovulation induction in polycystic ovarian syndrome, 133–134
 - poor responders, 102, 104, 111
 - preparations available, 170
 - treatment regimen, 20
 - urinary-derived, 82
 - see also* follicle-stimulating hormone (FSH); luteinizing hormone (LH)
- gonadotropin-releasing hormone (GnRH) agonists, 55–61
 - adjunct, 189
 - anti-Müllerian hormone levels, 60
 - conventional long-suppression protocol, 56–58
 - downregulation process, 56
 - efficacy, 56
 - flare effect, 56
 - flare protocol, 58–59
 - poor responders, 189
 - follicular recruitment
 - anti-Müllerian hormone levels, 60
 - dynamics, 59–60
 - functional cysts, 276
 - GnRH antagonists, comparison, 67–68, 167–168
- historical perspectives, 55
- intrauterine insemination with mild ovarian hyperstimulation, 31
- IVF babies, 74
- LH surge
 - control, 65
 - premature, prevention, 93, 302
 - suppressed, 61
- luteal phase stimulation, 95
- luteal phase support, 61, 295, 304–305
 - progesterone combination, 304
 - repeated dosing, 294
- mode of action, 56
- OHSS
 - ectopic pregnancy risk, 163
 - prediction, 59–60
 - risk, 59, 189
- oocyte donation, 86
- oocyte maturation, triggering of final, 282–287
 - GnRH antagonist protocol, 71–72
 - hCG luteal phase support, 303
 - luteal phase physiology, 284
 - metformin comparison, 136
 - oocyte efficiency parameters, 283–284
 - ovarian response management, 170
 - physiology, 282–283
 - polycystic ovarian syndrome, 135–136
 - protocols, 283
- ovarian reserve, 60–61
- ovulation triggering in poor responders, 103
- progesterone combination in luteal phase support, 304
- repeated dosing in luteal phase support, 294
- treatment, 56–61
- gonadotropin-releasing hormone (GnRH) antagonists, 65–75
 - adjunct, 189–190
 - advantages, 189
 - clomiphene citrate, 69
 - development, 65
 - dose finding study, 66
 - flexible protocol, 69
 - FSH dose increase, 69
 - GnRH agonists, 302
 - comparison, 67–68, 167–168
 - final oocyte maturation triggering, 71–72, 135–136, 146–147, 170
 - OHSS, 146–147
 - polycystic ovarian syndrome, 135–136

- human menopausal gonadotropin use, 69
- intrauterine insemination with mild ovarian hyperstimulation, 31
- IVF babies, 74
- LH surge
 - effects, 72–73
 - prevention, 93, 135
- luteal phase support
 - downregulated cycles, 293
 - OHSS, 151, 158
- mild IVF, 47
- mode of action, 65
- natural cycle IVF, 70–71
- OHSS, 73–74
 - agonist-triggered cycles, 146–147
 - coasting, 73
 - prevention, 73–74, 282
- older patients, 74
- oocyte donation, 86
- oral, 195
- oral contraceptive before IVF, 69–70
- outcome, 67–68, 167–168
- pituitary suppression in polycystic ovarian syndrome, 135
- poor responders, 72, 110–111, 189
- quality of life, short protocol vs long, 74
- recombinant FSH use, 70
- recombinant LH use, 70, 72
- single high-dose regimen, 66–67
- gonadotropin-releasing hormone (GnRH), pulsatile therapy in
 - hypogonadotropic hypogonadism, 214
 - side effects, 214–215
- GPR54 gene, 217
- growth factors, endometrial receptivity marker, 176
- growth hormone (GH)
 - adjunct in poor responders, 193
 - IGF-1 combination in
 - hypogonadotropic hypogonadism, 215–216
- hemorrhagic cysts, 276
- hemosiderosis, 216
- heparin binding-epidermal growth factor (HB-EGF), 176
- human chorionic gonadotropin (hCG)
 - adjunct, 192
 - anovulatory patients, 18, 20
 - luteal support in
 - hypogonadotropic patients, 18
- double stimulation (Shanghai protocol), 98
- implantation detection role, 182
- in vitro maturation, 135
- intrauterine insemination with mild ovarian hyperstimulation, 32
- LH activity, 201
- low dose in GnRH agonist-triggered cycles, 286
- low dose in OHSS prevention, 148, 294
- luteal phase support, 295, 302–304
 - dose individualization, 294
 - GnRH agonist-triggered cycles, 303
 - low-dose rescue, 286
 - OHSS risk, 303
 - outcome, 303
 - safety, 303
- micro-dosing strategy, 192
- outcomes, 303
- molecule, 81
- OHSS risk, 257
- OHSS stimulus, 143, 158
- oocyte maturation, luteal phase defect, 290, 302
- ovulation triggering in poor responders, 103
- perifollicular blood flow, 278
- pregnancy rates, potential impact, 259
- progesterone, stimulation of production, 302
- thalassemia, 217
- human menopausal gonadotropin (hMG)
 - development, 80
 - GnRH antagonist protocol, 69
 - LH
 - content, 82
 - variation in activity, 192
 - luteal phase stimulation, 94
 - rFSH comparison, 202
 - thalassemia, 217
- human reproduction, inefficiency, 173
- hydrolaparoscopy, transvaginal, 247
- hydrosalpinges, 277
- hydroxyethyl starch solution (HES), OHSS, 149–150, 160
- hyperinsulinemia
 - effects, 119
 - FSH levels, 21
- hyperplasia, 5, 15, 119, 123, **209**, 228, 230, 270
- hyperprolactinemia, 223–237
 - anovulatory patients, 15
 - antipsychotic medication, 237
 - causes, 228–231
 - physiological, 228–229
- clinical manifestations, 231
- diagnosis, 231
- dopamine agonists, 233–236
 - efficacy, 235
 - side effects, 235
- estrogen therapy, 236–237
- evaluation, 232
- galactorrhea, 231
- hypogonadism, 231
- hypothyroidism, 230, 237
- idiopathic, 232, 236
- imaging, 232
- infertility, 194, 227, 228
- laboratory tests, 232
- macroprolactinemia, 230
- management, 233–237
- men, 231
- osteopenia/osteoporosis, 231
- pharmacological agents, 229–231
- pituitary lesions, 232
- prolactinoma, 229
- radiation therapy, 237
- surgical treatment, 237
- withdrawal of therapy, 236
- hypogonadism
 - antipsychotic medication, 237
 - hyperprolactinemia, 231
- hypogonadotropic anovulation, 18, 79
- hypogonadotropic hypogonadism (HH)
 - classification, **209**
 - clinical features, 208
 - ERK1 and ERK2, 217–218
 - estrogen pretreatment, 216
 - FSH treatment with LH
 - pretreatment, 212
 - FSH treatment with LH supplementation, 203
 - GH/IGF-1 administration, 215–216
 - GnRH treatment, 214
 - side effects, 214–215
 - gonadotropin therapy, 210–211
 - complications, 213–214
 - outcome, 212–213
 - hCG treatment, 210
 - hMG treatment, 210
 - Kisspeptin-GPR54
 - complex, 217
 - kisspeptins, 195
 - LH treatment, 211–212
 - luteal phase support, 211
 - OHSS with gonadotropin therapy, 213–214
 - ovulation induction, 208–218
 - protocols, 208–218
 - hypothyroidism,
 - hyperprolactinemia, 230, 237

Index

- implantation
 - detecting, 182
 - endometrial receptivity, 182–183
 - hormones, 182–185
 - normal, 182
 - omics technologies, insights for understanding, 185
 - process of, 182
 - steroid hormones, 182–183
 - mechanism of action, 183–185
 - supraphysiological circulating hormone levels, effects on endometrial receptivity, 185–186
 - window of, *see* window of implantation (WOI)
- implantation failure, 256
 - assessment of endometrial receptivity to avoid, 180
 - concept, 182
 - displaced WOI in, 174
 - early onset, 182
 - Indian hedgehog (Ihh), uterine deletion, 185
 - IVF treatment, estrogen levels, 185
 - LIF levels in endometrial fluid, 175, 184
- implantation rate
 - estimation in natural cycles, 182
 - IVF treatment, definition, 182
- implantation window
 - delayed, 174
 - endometrial receptivity, 173–174
- in vitro fertilization (IVF)
 - babies in GnRH antagonist cycles, 74
 - conventional ovarian stimulation, 36–37, 50
 - efficacy, 49–50
 - embryo cryopreservation, 49
 - high progesterone, negative impact, 185
 - implantation failure, 185
 - intrauterine insemination with mild ovarian hyperstimulation, comparison, 33
 - luteal phase, support, 290–296
 - mild, 36–43
 - acceptance in the IVF community, 43
 - advantages, 37–41
 - comparison with conventional approach, 36–37, 50
 - costs, 50
 - criticisms, 42–43
 - definition, 47–48, 51
 - effectiveness, 41
 - efficacy, 49–50
 - embryo cryopreservation, 49
 - normal/high responders, 38–40
 - OHSS risk, 50
 - oocyte quantity, 49
 - oocytes, number retrieved, 48
 - ovarian hyperstimulation syndrome avoidance, 48
 - perinatal outcomes, 41
 - poor responders, 37, 50
 - pregnancy outcomes, 41
 - risks of ovarian stimulation, 48–49
 - status, 43
 - systematic reviews, 42
 - time to pregnancy, 50–51
 - natural cycle
 - GnRH antagonists, 70–71
 - implantation rate estimation, 182
 - oral contraceptive before in GnRH antagonist cycles, 69–70
 - polycystic ovarian syndrome, 134
 - OHSS risk, 134
 - poor responders, 101–106, 109–113
 - in vitro maturation (IVM) of oocytes
 - OHSS prevention, 134, 146
 - oocyte donation, 90
 - polycystic ovarian syndrome, 134–135
- Indian hedgehog (Ihh), uterine deletion leading to implantation failure, 185
- indicators of ovulation, traditional, 177
- individualized dosing for luteal phase support, hCG, 294
- individualized dosing for ovarian stimulation, 314–315
 - algorithms, 313–314
 - comparison, 313–314
 - conventional protocols comparisons, 315–316
 - FSH, 169
- indomethacin, 42
- inefficiency of human reproduction, 173
- infertility, hyperprolactinemia, 194, 227, 228
- inhibin B, ovarian reserve marker, 312
- inositol, anovulatory patients, 20, 21
- insulin resistance
 - anovulatory patients, 20
 - polycystic ovarian syndrome, 18, 20, 21, 119, 125
- insulin sensitizers, 1
 - anovulatory patients, 20–21, 133–134
 - polycystic ovarian syndrome, 125
- insulin-like growth factor 1 (IGF-1), GH combination in hypogonadotropic hypogonadism, 215–216
- intracytoplasmic sperm injection (ICSI), 74, 120, 296
- intrauterine insemination
 - polycystic ovarian syndrome, 124, 133
 - timing, 134
- intrauterine insemination with mild ovarian hyperstimulation, 29–33
 - antiestrogens, 31
 - aromatase inhibitors, 30
 - clomiphene citrate, 30
 - drug choice, 30–32
 - GnRH agonists, 31
 - GnRH antagonists, 31
 - gonadotropins, 30
 - hCG treatment, 32
 - indications, 29–30
 - IVF comparison, 33
 - LH surges, 31–32
 - luteal support, 31
 - multi-gestation pregnancy avoidance, 32–33
 - optimal timing, 32
 - outcome, 30, 31
 - progesterone use, 31
 - risks, 32–33
 - semen preparation, 33
 - treatment cycles, 32
- intrauterine synechiae, 269
- intravenous fluids, OHSS, 149, 160
- karyotype, 86, 88
 - oocyte donation, 88
- Kiss1* gene, 195
- Kisspeptin-GPR54 complex, 217
- kisspeptins, 195
- lactogenic hormone/lactotropin, *see* prolactin
- lactotroph adenoma, 229, 232, 233, 235, 237
- lactotroph(s)
 - hyperplasia, 228
 - prolactin secretion, 223
- laparoscopic electrocoagulation of the ovaries (LEO), 21–22
- laparoscopic ovarian diathermy
 - clomiphene citrate comparison, 132
 - efficacy, 132
 - long-term benefits, 132
 - polycystic ovarian syndrome, 132–133
 - premature ovarian failure, 248
 - resistance to treatment, 133

- laparoscopic ovarian drilling,
 - comparison with ultrasound-guided transvaginal drilling, 148
- laparoscopic ovarian multi-needle intervention (LOMNI), 248
- laparoscopic ovarian surgery
 - aromatase inhibitors comparison, 251
 - clomiphene citrate comparison, 251
- laparotomy, contraindicated in OHSS, 162
- laser ovarian cautery
 - complications, 248
 - method, 245–246
- letrozole, 1, 6
 - adverse effects, 9, 19
 - clomiphene citrate comparison, 22, 124–125
 - endometrium effects, 9
 - estrogen level lowering, 8, 9
 - laparoscopic ovarian surgery comparison, 251
 - luteal phase stimulation, 94
 - off label use, 125
 - OHSS prevention, 151
 - outcome of treatment, 10
 - ovarian androgens increased by, 195
 - polycystic ovarian syndrome, 10
 - poor responders, 111
 - pregnancy outcome, 10
 - safety, 9
 - treatment regimen, 18
- leukemia inhibitory factor (LIF),
 - implantation role, 175–176
- leuprolide acetate (LA), adjunct, 189
- lifestyle interventions, polycystic ovarian syndrome, 121–122
- luteal phase
 - defect cause, 296
 - defect during controlled ovarian stimulation, etiology, 302
 - definition, 290
 - double stimulation (Shanghai protocol), 98
 - GnRH agonist-triggered cycles
 - conventional support, 284–285
 - cycle segmentation, 286
 - intensive support, 285
 - low-dose hCG rescue, 286
 - physiology, 284
 - progesterone-free support, 286, 302–307
 - progesterone role, 291
- luteal phase stimulation, 93–95
 - clomiphene citrate, 95
 - fertility preservation of cancer patients, 93
 - follicular phase comparison, 94–95
 - GnRH agonists, 95
 - historical aspects, 93
 - human menopausal gonadotropin, 94
 - letrozole, 94
 - LH surge, 95
 - live birth data, 93
 - oocyte retrieval, 94
 - ploidy, 95
 - poor responders, 94
 - safety, 95
- luteal phase support
 - conventional, 284–285
 - definition, 290
 - duration, 296
 - estradiol supplementation, 305–306
 - GnRH agonists, 61, 295, 304–305
 - cryowarmed cycles, 304–305
 - GnRH agonist-triggered cycles, 305
 - oocyte maturation triggering, 135–136
 - progesterone combination, 304
 - safety, 305
 - GnRH antagonist protocol
 - downregulated cycles, 293
 - estradiol priming in poor responders, 112
 - hCG, 295, 302–304
 - dose individualization, 294
 - GnRH agonist-triggered cycles, 303
 - low-dose rescue, 286
 - OHSS risk, 303
 - outcome, 303
 - safety, 303
 - hypogonadotropic patients, 18, 211
 - intensive, 285
 - IVF, 290–296
 - luteal coasting, 294
 - onset, 295
 - personalized, 296
 - progesterone, 291
 - ascorbic acid combination, 294
 - aspirin combination, 295
 - co-treatments, 294–295
 - estradiol combination, 293
 - GnRH agonist combination, 304
 - intramuscular, 292
 - oral, 291
 - prednisolone combination, 294
 - subcutaneous, 292
 - vaginal, 292
 - progesterone-free, 286, 302–307
 - outcome, 307
- repeated GnRH agonist dosing, 294
- luteinization, premature, 55, 104
- luteinizing hormone (LH), 199–204
 - androgen production, 199
 - ceiling effect, 204
 - clomiphene citrate, levels increased by, 200
 - FSH comparison, 203
 - FSH treatment supplementation, 201–203, 205
 - general population, 201–202
 - outcome, 202
 - poor responders, 203
 - outcome, 204
 - human menopausal gonadotropin, 82
- hypogonadotropic
 - hypogonadism, 211–212
 - recombinant LH, 212
 - supplementation, 203
- implantation window, detecting, 182
- in deficient luteal phase, 302
- levels during ovarian stimulation, 200
- LH surge
 - array of responses, 55
 - control, 65
 - endometrial receptivity assessment, 177
 - following GnRH agonist-triggered cycles, duration, 282
- FSH, 79
- GnSAF, 200
- intrauterine insemination with mild ovarian hyperstimulation, 31–32
- luteal phase stimulation, 95
- monitoring of ovulation, 258
- premature
 - impact, 95
 - prevention
 - GnRH agonists, 93
 - GnRH antagonists, 135
 - OHSS risk, 59
 - oral contraceptives, 105
 - poor responders, 104, 105
 - progesterone, 96
 - progesterin-primed ovarian stimulation, 97
 - suppressed, 61
- low LH levels associated with low mature oocyte yield, 103
- main action, 199
- molecule, 81
- poor responders, supplementation for, 111
- recombinant
 - development, 80

Index

- luteinizing hormone (LH) (cont.)
 - hypogonadotropic hypogonadism, 212
 - role in folliculogenesis, 199
 - two-cell two-gonadotropin hypothesis, 199, 208
- luteinizing hormone/human chorionic gonadotropin receptor (LHCGR), 103
- luteotropic hormone/luteotropin, *see* prolactin
- macroprolactinemia, 224, 230
- malignancies, estrogen-dependent and fertility preservation, 9
- medroxyprogesterone acetate, progestin-primed ovarian stimulation, 96
- menotropins, *see* human menopausal gonadotropin (hMG)
- menstrual cycle, endometrial receptivity assessment, 177
- metformin
 - adjunct, 125, 136, 190–192
 - obstetric outcome, 125
 - pregnancy outcome, 125–126
 - anovulatory patients, 20–21
 - laparoscopic ovarian surgery comparison, 251
 - mechanism of action, 21
 - OHSS prevention, 136, 147–148, 191
 - treatment regimen, 21
- microadenoma, 233, 236
- microbiome, effect on endometrial receptivity, 179
- microRNAs, endometrial receptivity marker, 176
- mild stimulation IVF, 36–43
 - definition, 50, 146
 - OHSS prevention, 146
 - poor responders, 37, 50, 111
- miscarriage
 - aromatase inhibitors, 124
 - displaced implantation window in, 182
 - metformin, in reduction, 125, 191
 - prevention, myo-inositol pretreatment strategy, 137
 - recurrent
 - mucin levels, 175
 - oral retroprogesterone, 291
- mucins, 175
- Müllerian anomalies, ultrasound monitoring for ovulation induction, 268–269
- multigestation pregnancy
 - avoidance in intrauterine insemination with mild ovarian hyperstimulation, 32–33
 - clomiphene citrate, 3, 123
 - gonadotropin therapy in hypogonadotropic hypogonadism, 213
 - letrozole/clomiphene citrate comparison, 124
 - oocyte donation, 88
 - risk with gonadotropin therapy, 20
 - myo-inositol, pretreatment strategy, polycystic ovarian syndrome, 137
 - myometrial cyst, 267, 269
- N*-acetyl cysteine (NAC), polycystic ovarian syndrome, 127
- natural cycle frozen embryo transfer (FET), 258–259
- natural killer cells, endometrial receptivity assessment, 176, 177
- normogonadotropic anovulation, 18–19
- Noyes dating criteria, endometrial receptivity assessment, 176
- obesity
 - anovulatory patients, 16–17
 - clinical correlates, 120–121
 - effect on ART and pregnancy outcome, 120–121
 - effect on fertility, 120
 - influence on endometrial receptivity, 178
 - obstetrical complications, 120
 - pathophysiology, 120
 - polycystic ovarian syndrome, 119–122
 - metformin adjunct, 191
 - surgical interventions, 121–122
- omics sciences, endometrial receptivity assessment, 177–178, 185
- oocyte donation
 - definition, 85
 - donors
 - counseling, 85–86
 - for embryo transfer, 88–89
 - managing, 86
 - matching with recipient, 89
 - necessary steps for admittance, 85–86
 - gonadotropin therapy, 86
 - multiple pregnancy risk, 88
 - optimization of cycle, 90
 - ploidy, 90
 - predictive model, 88–89
 - recipients
 - assessment phase, 86
 - counseling, 86–88
 - for embryo transfer, 88–89
 - for genetic matching, 87–88
 - diagnoses, 86
 - hormone replacement therapy (HRT), 86
 - managing, 86–87
 - synchronization, 89–90
 - transvaginal retrieval, 86
 - oocyte maturation, triggering of final dual trigger, 113
 - GnRH agonists, 135–136, 170, 303
 - polycystic ovarian syndrome, 135–136
 - GnRH antagonist protocol, 71–72, 135–136, 146–147, 170
- oocyte retrieval
 - luteal phase stimulation, 94
 - poor responders, 104
- oocyte(s), 103, 134–135
 - cryopreservation, 9, 113, 145
 - immature, 146
 - meiosis, 218, 282, 283
 - optimal number, 166–167
- oral agents, 1–10
- oral contraceptive
 - before donation, 86
 - before IVF, GnRH antagonist cycles, 69–70
 - poor responders, 105, 112
 - LH surge prevention, 105
 - ovarian cysts, reduction, 190
- osteopenia/osteoporosis, hyperprolactinemia, 231
- ovarian adhesions, 248
- ovarian aging, risk factors, 110
- ovarian cancer risk, clomiphene citrate, 4, 19, 124
- ovarian cautery, 245, 247
 - bilateral, 246–247
 - consensus statements, 250
 - cost analysis, 249
 - drilling
 - complications, 248–249
 - methods, 245–248
 - outcomes, 246, 247
 - efficacy, 250
 - evidence-based meta-analyses, 250–252
 - expert opinion, 250
 - laparoscopic ovarian diathermy, 132, 133
 - premature ovarian failure, 248
 - laparoscopic ovarian drilling, 148
 - laparoscopic ovarian multi-needle intervention, 248
- laser
 - complications, 248
 - method, 245–246

- mechanism of action, 249–250
 ovarian adhesion risk, 248
 pelvic adhesion risk, 248
 polycystic ovarian syndrome, 132–133, 245–252
 premature ovarian failure, 248
 transvaginal hydrolaparoscopy, 247
 ultrasound-guided transvaginal ovarian needle drilling, 247–248
 unilateral, 246–247
 unipolar, 245
 ovarian cysts, 58, 141, 209, 277
 dermoid, 275–276
 development due to agonist phase of treatment, 189
 functional, 276
 hemorrhagic cysts, 276
 oral contraceptive pretreatment, reduced occurrence in, 190
 para-ovarian, 276
 ruptured, 160, 162
 ovarian failure, premature, 248
 ovarian hyperstimulation syndrome (OHSS), 141–151
 abdominal paracentesis, 162
 acute respiratory distress syndrome, 162
 anesthesia challenges, 145, 163
 anovulatory patients, 23–24
 anticoagulant therapy, 161
 anti-Müllerian hormone, 134
 ascites, 142, 145, 163
 management, 161–162
 ascites, management
 pigtail catheter placement, 162
 aspiration procedures, 161–162
 bilateral enlarged cystic ovaries, 141
 bone morphogenetic protein-15, 200
 cabergoline in prevention, 146, 149, 194
 calcium gluconate infusion in prevention, 150
 characteristics, 141, 282
 circulatory volume correction, 160–161
 classification, 141–143, 163
 clinical features, 163
 clomiphene citrate, 3
 coasting in prevention, 146, 147
 cryopreservation of embryos (freeze-all strategy), 37, 50–51, 255–261
 cycle cancellation, 148
 cyst rupture, 160, 162
 management, 162
 diuretic therapy, 160, 161
 dopamine agonists in prevention, 148–149
 early-onset, 74
 ectopic pregnancy, 160, 161, 163
 etiology, 158
 fluid balance, 159
 FSH use, 82
 GnRH agonists, 136
 ectopic pregnancy risk, 163
 oocyte maturation triggering, 146–147
 protective effect, 283
 risk, 59, 189
 GnRH antagonists, 93
 agonist comparison, 73, 190
 in prevention, 73–74, 282
 luteal phase administration, 151, 158
 pituitary desensitization, 145–146
 gonadotropin therapy
 hypogonadotropic hypogonadism, 213–214
 in prevention, 82
 risk, 20
 hCG
 low dose in prevention, 148, 294
 pathophysiology, 144
 pivotal stimulus, 143, 158
 hydroxyethyl starch solution, 149–150, 160
 incidence, 141, 282
 in-hospital management of severe/critical OHSS, 162
 intravenous albumin, 149–150, 160
 intravenous fluids, 149, 160
 laboratory features, 141–143, 163
 laparoscopic ovarian drilling/diathermy, 133, 148
 laparotomy, contraindicated, 162
 letrozole in prevention, 151
 low-dose aspirin adjunct, in reduction, 193
 luteal phase steroids, suppression of, 151
 management
 in-hospital, 162
 outpatient, 158–162
 mannitol in prevention, 149–150
 metformin in prevention, 136, 147–148, 191
 mild ovarian stimulation in prevention, 50, 146
 monitoring, 158
 number of oocytes retrieved, 311
 outpatient management of moderate/severe cases, 158–162
 ovarian torsion, 160
 management, 163
 pain management, 160
 paracentesis, 161–162
 pathophysiology, 134, 143, 158
 pleural effusion, 161–162
 prediction in long agonist cycles, 59–60
 predictive markers, 143–144
 pregnancy termination, 163
 preoperative antibiotic prophylaxis, 161
 prevention, 144–151
 antagonist protocols, 257
 cabergoline, 194
 coasting, antagonist cycles, 73
 dopamine agonists, 194
 embryo(s), elective freeze-all policy, 37, 50–51, 255–261
 in vitro maturation, 134, 146
 individualized dosing, 316
 mild ovarian stimulation in, 50, 146
 multigestation risk, 32–33
 outcome measures of effectiveness, 147
 primary, 144
 secondary, 144
 progestin-primed ovarian stimulation, 96
 quinagolide in prevention, 149
 reduced by individualized gonadotropin dosing, 170
 risk factors, 59, 134, 200, 214, 282, 303
 surgery, 162–163
 positioning of patients, 162
 symptoms, 143
 thoracocentesis, 162
 thromboembolism prevention, 160, 161, 163, 193
 transvaginal ultrasonography, 144
 ultrasound-guided aspiration, 162
 treatment, 158–163
 VEGF, 214
 venous thrombosis, risk, 161
 ovarian hyperstimulation, mild
 case against, 47–51
 efficacy, 49–50
 intrauterine insemination, 29–33
 ovarian physiology, 166
 ovarian reserve, 311
 anti-Müllerian hormone levels, 101, 110, 312
 antral follicle count, 312
 chronological age, 312
 definition, 311
 FSH marker, 312
 lower limits, defining, 311
 marker-based algorithms for individualized dosing, 313–314

Index

- ovarian reserve (cont.)
 - markers, 312–313
 - ovarian volume, 313
 - reference values, 311–312
- ovarian response
 - defining optimal, 166–167
 - genetic predictors, 312
 - predictors, 166, 168, 273, 312–313
 - relationship with endometrial receptivity, 167
- ovarian stimulation in poor responders, *see* poor response to ovarian stimulation
- ovarian torsion, 160
 - OHSS, management, 163
- ovarian volume
 - assessment, 272
 - ovarian reserve marker, 313
- ovaries
 - abnormalities, 273
 - assessment, 271–277
 - failure to visualize, 279
 - kissing, 275
 - laparoscopic electrocoagulation (LEO), 21–22
 - normal, 272–273
 - polycystic, 273
 - wedge resection, 245, 249
- overweight, anovulatory patients, 16–17
- ovulation induction
 - endometrium, assessment during, 269, 278
 - polycystic ovarian syndrome
 - adjunctive therapy, 125–127
 - aim of induction, 133
 - gonadotropin therapy, 133–134
 - oral agents, 122–125
 - thalassemia, 216–217
 - ultrasound monitoring, 265–279
 - ovulation, traditional indicators, 177
- paracentesis, OHSS, 161–162
- para-ovarian cysts, 276
- pelvic adhesions, 248, 272
 - endometrioma, 275
- pergolide, 234
- perifollicular blood flow (PFBF), Doppler analysis, 278
- peritoneal/pseudoperitoneal cysts, 277
- personalized embryo transfer, feasibility, 178
- pigtail catheter, OHSS, placement for ascites management, 162
- pinopodes, endometrial receptivity assessment, 176
- pioglitazone, 20, 21
- pituitary desensitization, OHSS, GnRH antagonists, 145–146
- pituitary suppression
 - GnRH antagonist/GnRH agonist comparison, 167–168
 - polycystic ovarian syndrome, GnRH antagonists, 135
- pleural effusion, OHSS, 161–162
- ploidy
 - double stimulation (Shanghai protocol), 98
 - gonadotropin therapy, 48–49
 - luteal phase stimulation, 95
 - maternal age in, 101
 - oocyte donation, 90
 - PCR assessment of aneuploidy, 49
 - risks of ovarian stimulation, 48–49
- polycystic ovarian syndrome (PCOS)
 - aromatase inhibitors, 1, 8–9, 124–125
 - clinical features, 119
 - clomiphene citrate, 122–124
 - clomiphene plus metformin, 125–126
 - controlled ovarian stimulation, 132–137
 - criteria for diagnosis, 119
 - definition, 119
 - dexamethasone, 126–127
 - frozen embryo transfer, outcomes, 259
 - GnRH agonists, oocyte maturation triggering, 135–136
 - GnRH antagonists, pituitary suppression, 135
 - historical aspects, 245
 - in vitro fertilization, 134
 - in vitro maturation, 134–135
 - inositol, 21
 - insulin resistance, 18, 20, 125
 - insulin sensitizers, 125
 - laparoscopic ovarian diathermy, 132, 133
 - laparoscopic ovarian drilling, 148
 - letrozole/clomiphene citrate comparison, 124–125
 - lifestyle interventions, 121–122
 - metformin adjunct, 125, 136, 190–192
 - obstetric outcome, 125
 - OHSS prevention, 136, 147–148, 191
 - pregnancy outcome, 125–126
 - myo-inositol, pretreatment strategy, 137
 - obesity, 119–122
 - surgical interventions, 121–122
 - OHSS risk, 282
- ovarian cautery, 245–252
- ovulation induction, 119–127
 - adjunctive therapy, 125–127
 - aim of, 133
 - gonadotropin therapy, 133–134
 - oral agents, 122–125
 - progesterin-primed ovarian stimulation, 96
 - weight loss, 121–122
- polycystic ovaries, 273, 275
 - anti-Müllerian hormone levels, 134
 - diagnostic criteria, 119
- polymerase chain reaction, assessment of aneuploidy, 49
- polyps
 - feeding vessel, 273
 - sonohysterography, 270–271, 272
- poor response to ovarian stimulation, vii, 101–106, 109–113
 - adjuvants, 105, 112, 113
 - age of women, 203
 - androgen adjuvant, 112
 - anti-Müllerian hormone levels, 101, 110
 - classification
 - Bologna criteria, 101, 109
 - Bologna-Poseidon comparison, **102**
 - Poseidon criteria, 101–102, 109
 - clomiphene citrate, 111
 - corifollitropin alfa, 111
 - definition, 109
 - diminished reserve patients, 104–105
 - extremely low ovarian reserve, 105
 - monitoring follicular growth, 104
 - oocyte retrieval and embryo culture, 104–105
 - trigger efficacy, 104
 - double stimulation (Shanghai protocol), 98
 - dual trigger of final oocyte maturation, 113
 - embryo banking strategy, 113
 - estradiol priming, 112
 - estrogen adjunct, 190
 - freeze-all strategy, 113
 - FSH with LH supplementation, 203
 - outcome, **204**
 - GnRH agonists, 110–111
 - ovulation triggering, 103
 - GnRH antagonists, 72, 110–111
 - advantages, 189
 - gonadotropins, 111
 - growth hormone adjunct, 193

- growth hormone adjuvant, 112
- iatrogenic factors, 110
- incidence during COS, 101
- IVF patients, dexamethasone
 adjunct, 190
- letrozole, 111
- LH supplementation, 111
- long-acting recombinant FSH,
 111
- luteal phase stimulation, 94
- mild protocol, 37, 50, 111
- oral contraceptive, 105, 112
- predictive markers of ovarian
 response, 110
- progesterin-primed ovarian
 stimulation, 96, 102, 104
- risk factors, 110
- sufficient reserve patients,
 102–104
 - genetic screening, 103–104
 - monitoring follicular growth,
 102–103
 - trigger efficacy, 103
- treatment regimens, 102–113
- Poseidon (Patient-Oriented Strategies
 Encompassing
 Individualized Oocyte
 Number) criteria, poor
 responders, 101–102, 109
- posterior intramural fibroids, 266
- prednisolone, progesterone
 combination for luteal
 phase support, 294
- pregnancy
 - ectopic, 124, 160, 161, 163
 - prolactin levels, 228
- pregnancy loss
 - clomiphene citrate, 4
 - corpus luteum removal, 291
 - obesity, 120
 - potential role of microorganisms,
 179
- pregnancy termination, OHSS, 163
- preimplantation genetic screening,
 indicators, 258
- premature ovulation, preventing, 93
- progesterone
 - endometrial preparation, 259
 - endometrial receptivity role,
 182–183
 - freeze-all policy
 - in high, 185
 - in premature elevation,
 257–258
- GnRH agonist combination in
 luteal phase support,
 304
- gonadotropin secretion,
 regulation, 97
- intrauterine insemination with
 mild ovarian
 hyperstimulation, 31
- LH surge, suppression effect, 96
- luteal phase support, 291
 - ascorbic acid combination, 294
 - aspirin combination, 295
 - co-treatments, 294–295
 - estradiol combination, 293
 - GnRH agonist combination,
 304
 - prednisolone combination, 294
 - subcutaneous administration,
 292
 - vaginal administration, 292
- mechanism of action during
 implantation, 183–185
- negative impact of high level, 185
- ovarian stimulation primed by,
 93–98
- premature elevation, 257–258
- stimulation protocols, 98
- progesterin-primed ovarian
 stimulation (PPOS),
 93–98
 - advantages, 96
 - efficacy, 96, 98
 - LH surge, prevention, 97
 - medroxyprogesterone acetate, 96
 - OHSS risk, 96
 - polycystic ovarian syndrome, 96
 - poor responders, 96, 102, 104
 - protocol, 95–97
 - safety, 97
- prolactin, 223–227
 - biosynthesis, 223–224
 - effects, 226–227
 - functions, 227
 - hypothyroidism effects, 230, 237
 - receptors, 224–225
 - secretion, 223, 225–226
 - pulsatile, 225
 - regulation, 226
 - sources, 227
 - structure, 224
- prolactinoma, 229
- prostaglandins, endometrial
 receptivity marker, 176
- protocols for ovarian stimulation,
 166–170
 - defining optimal ovarian
 response, 166–167
 - individualization
 - future expectations, 170
 - gonadotropin dosing, 168–170
 - general ART population, 169
 - high responders, 170
 - poor responders, 169–170
 - pituitary suppression, 167–168
 - limited range, 166
 - ovarian physiology, 166
 - standardized, 166
- quinagolide, 233, 235
 - OHSS prevention, 149
- radiation therapy,
 hyperprolactinemia,
 237
- recurrent implantation failures
 (RIF)
 - displaced implantation window,
 174, 178
 - influence of natural killer cells,
 177
- renal failure, hyperprolactinemia,
 230
- rosiglitazone, 8, 20, 21
- Rotterdam consensus, polycystic
 ovarian syndrome, 24,
 119, 125, 273
- selective estrogen receptor
 modulators (SERMs), 1,
 2, 19
- semen preparation, intrauterine
 insemination with mild
 ovarian
 hyperstimulation, 33
- sex hormone-binding globulin
 (SHBG), 21, 119
- single-nucleotide polymorphism,
 258
- smoking
 - cessation for anovulatory
 patients, 17
 - FSH levels, 17
- sonohysterography, 270–271, 272
- Stein–Leventhal syndrome, *see*
 polycystic ovarian
 syndrome (PCOS)
- steroid hormones, mechanism of
 action during
 implantation, 183–185
- submucous fibroids, 266
- supraphysiological circulating
 hormone levels, effects
 on endometrial
 receptivity, 185–186
- surgery
 - hyperprolactinemia, 237
 - OHSS, 162–163
 - positioning of patients, 162
- tamoxifen
 - anovulatory patients, 19
 - with clomiphene citrate, 6
- testosterone, poor responders, 194
- thalassemia, ovulation induction,
 216–217
- thoracocentesis, OHSS, 162
- thromboembolism, OHSS,
 prevention, 160, 161,
 163, 193
- transvaginal hydrolaparoscopy, 247
- transvaginal ultrasound-guided
 aspiration, 162
- Trendelenberg position, OHSS, 162

Index

- two-cell two-gonadotropin
 hypothesis, 199, 208
tyrosine hydroxylase, 226

ultrasonography, endometrial
 receptivity assessment, 177

ultrasound monitoring for
 ovulation induction, 265–279

adenomyosis, 267–268

antral follicle count, 272–273

endometrium
 assessment, 269, 278

polyps, 269

hydrosalpinges, 277

methods, 277

Müllerian anomalies, 268–269

ovary assessment, 271–277, 279

perifollicular blood
 flow, 278

peritoneal/pseudoperitoneal
 cysts, 277

problems encountered, 279

sonohysterography, 270–271

three-dimensional technique, 278
- timing, 278

transvaginal two-dimensional,
 277

uterine fibroids, 265–267

VOCAL techniques, 278

ultrasound-guided transvaginal
 ovarian needle drilling
 (UTND), 148, 247–248

unicornuate uterus, 269

urofollitropin, 80

uterine fibroids, 265–267

uterine natural killer cells (uNK),
 endometrial receptivity
 assessment, 176, 177

uterus
 anomalies, 268–269

assessment, 265–271

endometrium, assessment during
 ovulation induction,
 269

fibroids, 265–267

intrauterine synechiae, 269

ovulation induction pretreatment
 evaluation, 265

progesterone effects, 291

septate, 269
- sonohysterography, 270–271

subseptate, 268

unicornuate, 269

vascular endothelial growth factor
 (VEGF), OHSS, 214

venous thrombosis, OHSS, 161

vitrification, process, 256

weight reduction, anovulatory
 patients, 16–17

window of implantation
 (WOI)
 concept introduction, 182

definition, 173

displaced in implantation failure,
 174

displacement, obesity as cause of,
 178

lipidomic signature, 178

progesterone, role of, 183

World Health Organization
 (WHO), anovulatory
 patient classification, 15

zucломiphene, 2